Vulvovaginal candidiasis: comparative efficacy of antifungal treatments

  • Qin F & al.
  • Infect Drug Resist
  • 1 Jan 2018

  • curated by Pavankumar Kamat
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

According to a meta-analysis published in Infectious and Drug Resistance, antifungal drugs have variable efficacy in the treatment of vulvovaginal candidiasis (VVC), fluconazole being the most effective.

Researchers conducted a meta-analysis of 41 randomised trials that compared the efficacy of antifungal drugs vs placebo in the treatment of VVC.

The pooled results of pairwise meta-analysis showed that fluconazole (OR, 6.45; 95% Credible Interval [CrI], 4.42–9.41), clotrimazole (OR, 2.99; 95% CrI 1.61–5.55), miconazole (OR, 5.96; 95% CrI, 3.17–11.2), itraconazole (OR, 2.29; 95% CrI 1.21–4.33), ketoconazole (OR, 2.40; 95% CrI 1.55–3.71), butoconazole (OR, 1.18; 95% CrI 1.06–1.31), and terconazole (OR, 5.60; 95% CrI 2.78–11.3) were more effective in the treatment of VVC vs placebo. The surface under the cumulative ranking curve values for each drug were as follows: fluconazole (91.5%), clotrimazole (61.8%), miconazole (33.8%), itraconazole (50.5%), ketoconazole (42.8%), econazole (46.8%), butoconazole (82.2%), terbinafine (20.9%), and terconazole (65.0%) vs placebo (0.5%).

The authors said: “The American and European guidelines for the treatment of VVC, based on a large number of evidence-based clinical practice, recommended the use of fluconazole (150 mg) for the treatment of moderate-to-severe VVC, which is consistent with our results." The authors call for further high-quality studies with large sample sizes to strengthen the results.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit